General Information of Drug Combination (ID: DCI75AC)

Drug Combination Name
Regadenoson Adenosine
Indication
Disease Entry Status REF
Obesity Phase 1 [1]
Component Drugs Regadenoson   DM76VHG Adenosine   DMM2NSK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Regadenoson
Disease Entry ICD 11 Status REF
Radionuclide imaging N.A. Approved [2]
Regadenoson Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine A2a receptor (ADORA2A) TTM2AOE AA2AR_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Indication(s) of Adenosine
Disease Entry ICD 11 Status REF
Paroxysmal supraventricular tachycardia BC81.Z Approved [3]
Adenosine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Adenosine A2b receptor (ADORA2B) TTNE7KG AA2BR_HUMAN Modulator [6]
------------------------------------------------------------------------------------
Adenosine Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 5 (ABCC5) DTYVM24 MRP5_HUMAN Substrate [7]
Equilibrative nucleoside transporter 1 (SLC29A1) DTXD1TQ S29A1_HUMAN Substrate [8]
------------------------------------------------------------------------------------
Adenosine Interacts with 2 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Sulfotransferase 1A1 (SULT1A1) DEYWLRK ST1A1_HUMAN Metabolism [9]
Adenosine aminohydrolase (ADA) DEDQHBV ADA_HUMAN Metabolism [10]
------------------------------------------------------------------------------------
Adenosine Interacts with 58 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Equilibrative nucleoside transporter 1 (SLC29A1) OTLOOZZS S29A1_HUMAN Increases Uptake [11]
L-lactate dehydrogenase A chain (LDHA) OTN7K4XB LDHA_HUMAN Increases ADR [12]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Phosphorylation [13]
Dipeptidyl peptidase 4 (DPP4) OT16MVL9 DPP4_HUMAN Decreases Expression [13]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Phosphorylation [13]
Toll-like receptor 4 (TLR4) OTP7ML3S TLR4_HUMAN Increases Expression [14]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [15]
Dickkopf-related protein 1 (DKK1) OTRDLUSP DKK1_HUMAN Increases Expression [16]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Increases Expression [16]
Pro-epidermal growth factor (EGF) OTANRJ0L EGF_HUMAN Increases Expression [16]
Protransforming growth factor alpha (TGFA) OTPD1LL9 TGFA_HUMAN Increases Secretion [16]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [16]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Increases Expression [17]
Insulin-like growth factor I (IGF1) OTIIZR61 IGF1_HUMAN Affects Expression [16]
Monocyte differentiation antigen CD14 (CD14) OT83GJ47 CD14_HUMAN Increases Expression [14]
Adenosine receptor A3 (ADORA3) OTHO1BLK AA3R_HUMAN Increases Expression [5]
Bone morphogenetic protein 2 (BMP2) OT23T37S BMP2_HUMAN Increases Expression [16]
Bone morphogenetic protein 4 (BMP4) OTPZMDFH BMP4_HUMAN Increases Expression [16]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Increases Activity [18]
Cyclic AMP-responsive element-binding protein 1 (CREB1) OT1MDLA1 CREB1_HUMAN Increases Expression [16]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Increases Phosphorylation [16]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Increases Expression [16]
Adenosine receptor A2a (ADORA2A) OTVRBZ0I AA2AR_HUMAN Affects Binding [19]
Adenosine receptor A1 (ADORA1) OTI7X39E AA1R_HUMAN Affects Binding [19]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Increases Expression [16]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) OTUE7Z91 MP2K2_HUMAN Increases Phosphorylation [16]
Bone morphogenetic protein receptor type-1A (BMPR1A) OTQOA4ZH BMR1A_HUMAN Increases Expression [16]
Glial cell line-derived neurotrophic factor (GDNF) OT8ICC4Z GDNF_HUMAN Increases Secretion [16]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Increases Phosphorylation [16]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [20]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Affects Expression [16]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [21]
Placenta growth factor (PGF) OT5MF5DJ PLGF_HUMAN Increases Secretion [16]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Expression [16]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [20]
Transforming growth factor beta-2 proprotein (TGFB2) OTC0TXEP TGFB2_HUMAN Increases Expression [16]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Increases Phosphorylation [16]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Localization [20]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [22]
FAS-associated death domain protein (FADD) OTV7GFHH FADD_HUMAN Decreases Expression [15]
Frizzled-5 (FZD5) OTXFFY56 FZD5_HUMAN Increases Expression [16]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [22]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [22]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [15]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Increases Expression [5]
Estrogen receptor beta (ESR2) OTXNR2WQ ESR2_HUMAN Increases Expression [17]
Frizzled-3 (FZD3) OTIWDN78 FZD3_HUMAN Increases Expression [16]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Expression [22]
Peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PPARGC1A) OTHCDQ22 PRGC1_HUMAN Increases Expression [23]
Lymphoid enhancer-binding factor 1 (LEF1) OTWS5I5H LEF1_HUMAN Increases Expression [16]
Lymphocyte antigen 96 (LY96) OTN4HXA2 LY96_HUMAN Increases Expression [14]
Mitogen-activated protein kinase 11 (MAPK11) OT0AS010 MK11_HUMAN Increases ADR [12]
Tyrosine-protein phosphatase non-receptor type 12 (PTPN12) OT5WA666 PTN12_HUMAN Increases ADR [12]
Sodium/nucleoside cotransporter 2 (SLC28A2) OTFYZK8R S28A2_HUMAN Increases Transport [24]
Equilibrative nucleoside transporter 3 (SLC29A3) OTGLX8XU S29A3_HUMAN Affects Transport [25]
Purine nucleoside phosphorylase (PNP) OTO5NIJ2 PNPH_HUMAN Increases ADR [12]
Equilibrative nucleoside transporter 2 (SLC29A2) OTUAOB8T S29A2_HUMAN Increases Uptake [26]
Sodium/nucleoside cotransporter 1 (SLC28A1) OTXWVV9O S28A1_HUMAN Affects Transport [27]
------------------------------------------------------------------------------------
⏷ Show the Full List of 58 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Hypertrophic Cardiomyopathy DCXADT2 N. A. Phase 4 [28]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00859833) Effects of Body Mass Index on the Hyperemic Response to Regadenoson
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5596).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2844).
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Adenosine up-regulates vascular endothelial growth factor in human macrophages. Biochem Biophys Res Commun. 2010 Feb 12;392(3):351-6. doi: 10.1016/j.bbrc.2010.01.023. Epub 2010 Jan 11.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Role of MRP4 and MRP5 in biology and chemotherapy. AAPS PharmSci. 2002;4(3):E14.
8 Nitric oxide reduces adenosine transporter ENT1 gene (SLC29A1) promoter activity in human fetal endothelium from gestational diabetes. J Cell Physiol. 2006 Aug;208(2):451-60.
9 Regulation of sulfate assimilation in plants: 7. Cysteine inactivation of adenosine 5'-phosphosulfate sulfotransferase in Lemna minor L. Plant Physiol. 1978 Mar;61(3):342-7.
10 A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15676-81.
11 Functional role of the polymorphic 647 T/C variant of ENT1 (SLC29A1) and its association with alcohol withdrawal seizures. PLoS One. 2011 Jan 24;6(1):e16331. doi: 10.1371/journal.pone.0016331.
12 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
13 Adenosine downregulates DPPIV on HT-29 colon cancer cells by stimulating protein tyrosine phosphatase(s) and reducing ERK1/2 activity via a novel pathway. Am J Physiol Cell Physiol. 2006 Sep;291(3):C433-44.
14 Adenosine reduces cell surface expression of toll-like receptor 4 and inflammation in response to lipopolysaccharide and matrix products. J Cardiovasc Transl Res. 2011 Dec;4(6):790-800. doi: 10.1007/s12265-011-9279-x. Epub 2011 May 3.
15 Intracellularly transported adenosine induces apoptosis in HuH-7 human hepatoma cells by downregulating c-FLIP expression causing caspase-3/-8 activation. Biochem Pharmacol. 2007 May 15;73(10):1665-75. doi: 10.1016/j.bcp.2007.01.020. Epub 2007 Jan 18.
16 Adenosine and Cordycepin Accelerate Tissue Remodeling Process through Adenosine Receptor Mediated Wnt/-Catenin Pathway Stimulation by Regulating GSK3b Activity. Int J Mol Sci. 2021 May 25;22(11):5571. doi: 10.3390/ijms22115571.
17 Estrogenic Effects of the Extracts from the Chinese Yam (Dioscorea opposite Thunb.) and Its Effective Compounds in Vitro and in Vivo. Molecules. 2018 Jan 23;23(2):11. doi: 10.3390/molecules23020011.
18 Activation of airway cl- secretion in human subjects by adenosine. Am J Respir Cell Mol Biol. 2004 Aug;31(2):140-6. doi: 10.1165/rcmb.2004-0012OC. Epub 2004 Mar 23.
19 New 2,6,9-trisubstituted adenines as adenosine receptor antagonists: a preliminary SAR profile. Purinergic Signal. 2007 Sep;3(4):339-46. doi: 10.1007/s11302-007-9068-9. Epub 2007 Sep 19.
20 Thymidine-dependent attenuation of the mitochondrial apoptotic pathway in adenosine-induced apoptosis of HL-60 cells. J Cancer Res Clin Oncol. 2001 Sep;127(9):570-6. doi: 10.1007/s004320100264.
21 Apoptosis induced by nucleosides in the human hepatoma HepG2. World J Gastroenterol. 2005 Oct 28;11(40):6381-4. doi: 10.3748/wjg.v11.i40.6381.
22 Adenosine-induced caspase-3 activation by tuning Bcl-XL/DIABLO/IAP expression in HuH-7 human hepatoma cells. Cell Biol Toxicol. 2010 Aug;26(4):319-30. doi: 10.1007/s10565-009-9145-7. Epub 2010 Jan 9.
23 A cardiac-specific robotized cellular assay identified families of human ligands as inducers of PGC-1 expression and mitochondrial biogenesis. PLoS One. 2012;7(10):e46753. doi: 10.1371/journal.pone.0046753. Epub 2012 Oct 3.
24 Molecular cloning, functional expression and chromosomal localization of a cDNA encoding a human Na+/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol. 1998 Oct-Dec;15(4):203-11. doi: 10.3109/09687689709044322.
25 Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3. Am J Physiol Gastrointest Liver Physiol. 2009 Apr;296(4):G910-22. doi: 10.1152/ajpgi.90672.2008. Epub 2009 Jan 22.
26 Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem J. 1997 Dec 15;328 ( Pt 3)(Pt 3):739-43. doi: 10.1042/bj3280739.
27 Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol. 1997 Feb;272(2 Pt 1):C707-14. doi: 10.1152/ajpcell.1997.272.2.C707.
28 ClinicalTrials.gov (NCT03249272) Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve